Chimerix (NASDAQ:CMRX) Shares Pass Below 200 Day Moving Average of $0.99

Chimerix, Inc. (NASDAQ:CMRX) shares passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.99 and traded as low as $0.88. Chimerix shares last traded at $0.88, with a volume of 267,453 shares trading hands.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded shares of Chimerix from a “sell” rating to a “hold” rating in a research note on Saturday, June 8th.

Chimerix Stock Performance

The company’s 50 day simple moving average is $0.94 and its 200-day simple moving average is $0.99.

Chimerix (NASDAQ:CMRX) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.04). Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 41.32%. During the same quarter in the prior year, the firm posted ($0.24) EPS. On average, equities research analysts forecast that Chimerix, Inc. will post -0.85 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Chimerix

Several institutional investors have recently made changes to their positions in the business. Acadian Asset Management LLC lifted its stake in shares of Chimerix by 15.5% in the 1st quarter. Acadian Asset Management LLC now owns 2,174,813 shares of the biopharmaceutical company’s stock worth $2,304,000 after purchasing an additional 291,981 shares during the period. Koshinski Asset Management Inc. bought a new position in shares of Chimerix in the 1st quarter worth approximately $42,000. Marquette Asset Management LLC lifted its stake in shares of Chimerix by 24.3% in the 1st quarter. Marquette Asset Management LLC now owns 116,009 shares of the biopharmaceutical company’s stock worth $123,000 after purchasing an additional 22,709 shares during the period. Pale Fire Capital SE lifted its stake in shares of Chimerix by 113.6% in the 4th quarter. Pale Fire Capital SE now owns 211,214 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 112,318 shares during the period. Finally, Vestal Point Capital LP bought a new stake in Chimerix during the 4th quarter worth approximately $1,348,000. Institutional investors own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.